Floatz logo

Conestat Alfa

Common Variable Immunodeficiency

IMMUNOe Research Centersprotein_peptidePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Common Variable Immunodeficiency cohort.

Asset / SponsorPhaseRating
Thiotepa
University of Florida
Phase 2BB
Human Immunoglobulins
Grifols Therapeutics LLC
Phase 3B
Fludarabine
Paul Szabolcs
Phase 2CCC
Melphalan
Paul Szabolcs
Phase 2CCC
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Paul Szabolcs
Phase 2CCC

View all 18 →

Same molecule, other indications

Conestat Alfa is also rated in:

hereditary angioedemaDormant
BBB
Indicative · Phase 3
74 / 100
View asset →
injuryDormant
B
Indicative · Phase 3
60 / 100
View asset →
infectious disease with sepsisDormant
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →